220 related articles for article (PubMed ID: 36702831)
21. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
[TBL] [Abstract][Full Text] [Related]
22. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
23. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.
Wang M; Jia J; Cui Y; Peng Y; Jiang Y
Cell Death Dis; 2021 Nov; 12(11):1065. PubMed ID: 34753903
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis of the Tumor Immune Microenvironment Landscape in Glioblastoma Reveals Tumor Heterogeneity and Implications for Prognosis and Immunotherapy.
Zhao R; Pan Z; Li B; Zhao S; Zhang S; Qi Y; Qiu J; Gao Z; Fan Y; Guo Q; Qiu W; Wang S; Wang Q; Zhang P; Guo X; Deng L; Xue H; Li G
Front Immunol; 2022; 13():820673. PubMed ID: 35309323
[TBL] [Abstract][Full Text] [Related]
26. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
Majd N; de Groot J
Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
[No Abstract] [Full Text] [Related]
27. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
[TBL] [Abstract][Full Text] [Related]
29. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
[TBL] [Abstract][Full Text] [Related]
30. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
31. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model.
Crommentuijn MHW; Schetters STT; Dusoswa SA; Kruijssen LJW; Garcia-Vallejo JJ; van Kooyk Y
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303613
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
33. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
34. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
35. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
36. Functional virus-specific memory T cells survey glioblastoma.
Ning J; Gavil NV; Wu S; Wijeyesinghe S; Weyu E; Ma J; Li M; Grigore FN; Dhawan S; Skorput AGJ; Musial SC; Chen CC; Masopust D; Rosato PC
Cancer Immunol Immunother; 2022 Aug; 71(8):1863-1875. PubMed ID: 35001153
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
38. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
39. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
Sener U; Ruff MW; Campian JL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]